GOTHENBURG, Sweden, July 3, 2024 /PRNewswire/ — Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q2, 2024. The presentation will be held in English.
Time: Wednesday 17 July, 2024 at 10.00 a.m. CET.
To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | Vitrolife Group
Vitrolife Group participants:
Bronwyn Brophy O´Connor, CEO
Patrik Tolf, CFO
The press release for the interim report will be released at 8.00 CET on the same day.
Before the conference call, presentation material will be available at the company web page.
A recorded version of the telephone conference will be available for seven days on number +44 (0) 20 3451 9993 (International), access code 7692641#.
Gothenburg, 3 July 2024
VITROLIFE AB (publ)
Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/vitrolife-ab–publ-/r/conference-call-interim-report,c4010494
The following files are available for download:
|
Conference call interim report |
SOURCE Vitrolife AB (publ)
Guests had an opportunity to meet Gabby Thomas, win health-focused prizes, and learn simple ways…
NEW YORK CITY, NY / ACCESS Newswire / January 10, 2026 / The phrase best…
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…